Exact Sciences Corp at Robert W Baird Global Healthcare Conference Transcript
All right. We're going to go ahead and get started. I'm Catherine Schulte, I cover Life Sciences and Diagnostics here at Baird. Very excited to have Exact Sciences presenting today. From the company, we have Jeff Elliott, CFO. If you have any questions at all during the presentation, you can e-mail them to [email protected], and I will pass them along to Jeff. So with that, I'll turn it over to Jeff for some introductory comments, and then we'll move into Q&A.
Thank you, Catherine. It's great to be back here again at Baird. So we are coming off of a very strong quarter. In the second quarter, we grew by over 90%, we generated $200 million of revenue with 70% gross -- 74% gross margins. And today, our market share is under 6%. So there's a long runway ahead.
This market for colon cancer screening in the U.S. is 87 million people, so it's a huge market. Our long-term goal is to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
